Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Imprimer: 0893-9675
ISSN En ligne: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i1.30
pages 17-30

Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid Leukaemia

David T. Yeung
Haematology Department, SA Pathology (RAH Site), Centre for Cancer Biology, and University of Adelaide, Adelaide, Australia.
Timothy P. Hughes
Haematology Department, SA Pathology (RAH Site), Centre for Cancer Biology, and University of Adelaide, Adelaide, Australia

RÉSUMÉ

Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein as a result of the t(9;22) chromosomal translocation. The elucidation of its molecular pathogenesis led to the identification of a therapeutic target and the subsequent synthesis and introduction of a small-molecule inhibitor for this target, imatinib. Because CML is the first disease successfully treated by targeted kinase inhibition, it served as a paradigm for discovery of disease mechanism and drug development in other diseases in which constitutive kinase expression plays a central role in pathogenesis. Despite the spectacular success of imatinib, not all CML patients derive great benefit from it. This review will cover some of the currently known prognostic markers of disease response and potential resistance mechanisms.


Articles with similar content:

Pediatric Brain Tumors: Genomics and Epigenomics Pave the Way
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 3-4
Adam M. Fontebasso , Nada Jabado
Targeting PGE2 Signaling in Tumor Progression and Angiogenesis
Onco Therapeutics, Vol.5, 2014, issue 3-4
Federica Finetti, Erika Terzuoli, Marina Ziche, Lorenzo Bazzani, Sandra Donnini
Cancer Genetics/Epigenetics and the X Chromosome: Possible New Links for Malignant Glioma Pathogenesis and Immune-Based Therapies
Critical Reviews™ in Oncogenesis, Vol.11, 2000, issue 1
Waldemar Debinski, Akiva Mintz
Raf Kinase Inhibitory Protein (RKIP) as a Metastasis Suppressor: Regulation of Signaling Networks in Cancer
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Marsha Rich Rosner, Ali E. Yesilkanal
Drug Development for Metastasis Prevention
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Steven M. Dubinett, Yari Fontebasso